Protecting Medicare from Excessive Price Increases Act of 2018
Latest action · Mar 9, 2018 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 1, 2018
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Protecting Medicare from Excessive Price Increases Act of 2018
This bill requires a drug manufacturer to pay a Medicare rebate on a single-source drug or biological in accordance with the extent to which the manufacturer's average sales price for the drug or biological increases faster than inflation.
Cosponsors 4
Members who signed on, in the order they did. Signatures ran from Mar 13, 2018 to Apr 18, 2018.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-OR | Earl Blumenauer | Mar 13, 2018 | |
| D-TX | Sheila Jackson Lee | Mar 13, 2018 | |
| D-AZ | Raúl M. Grijalva | Apr 10, 2018 | |
| D-CA | Judy Chu | Apr 18, 2018 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 1, 2018 |
| Health Subcommittee | Referred Mar 2, 2018 | |
| House | Ways and Means Committee | Referred Mar 1, 2018 |
| Health Subcommittee | Referred Mar 9, 2018 |
Actions 4
Everything that happened, newest first.
- Mar 9, 2018Referred to the Subcommittee on Health.
- Mar 2, 2018Referred to the Subcommittee on Health.
- Mar 1, 2018Introduced in House
- Mar 1, 2018Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 164, no. 37, March 1, 2018, page H1342.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend title XVIII of the Social Security Act to require drug manufacturers to pay a Medicare part B rebate for certain drugs if the price of such drugs increases faster than inflation.
- Short Titles as Introduced
- Protecting Medicare from Excessive Price Increases Act of 2018
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Mar 1, 2018Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.